United Therapeutics (UTHR) Tops Q4 EPS by 51c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
United Therapeutics Corp. (UTHR) PT Raised to $175 at Oppenheimer
February 23, 2017 9:27 AM ESTOppenheimer raised its price target on United Therapeutics Corp. (NASDAQ: UTHR) to $175.00 (from $160.00) while maintaining a Outperform rating.
Analyst Hartaj Singh commented, "United Therapeutics (UTHR) reported 4Q16 sales/earnings and provided a business update to investors earlier today. The company reported a... More
